SEC Filing Summary: Synthetic Blood International, Inc. (10-K)
Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Fiscal year ended April 30, 2004.
Business Stage: Development stage enterprise with no commercial revenues. The company focuses on developing Oxycyte, a perfluorocarbon-based synthetic blood substitute. Other products, Fluorovent (lung treatment) and an implanted glucose biosensor, are currently on hold pending additional financing.
Key Milestone: Completed Phase I clinical trials for Oxycyte in December 2003 with results meeting safety expectations. Preparing for Phase II trials.
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 | Fiscal 2002 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Other Income (Interest/Rental) | $18,002 | $48,558 | $130,288 |
| Total Expenses | $2,267,205 | $2,275,895 | $3,618,101 |
| Net Loss | $(2,249,203) | $(2,227,337) | $(3,487,813) |
| Cash and Equivalents (End of Period) | $302,310 | $178,442 | $2,424,015 |
| Working Capital | $127,592 | $236,869 | $2,352,474 |
| Accumulated Deficit | $(20,949,933) | $(18,700,730) | $(16,473,393) |
Material Changes vs. Prior Period
- Expenses: Total expenses remained relatively flat compared to 2003 ($2.27M vs $2.28M). Research and Development (R&D) expenses decreased 11% to $1.28M due to reduced spending on non-priority products (Fluorovent and biosensor) and the timing of animal studies. General and Administrative (G&A) expenses increased 18% to $991K, driven by $99K in amortization of deferred compensation (stock options) and a $40K bonus to the President.
- Liquidity: Cash increased from $178K to $302K, primarily due to a private placement of common stock raising approximately $2.0M during the fiscal year. However, working capital declined from $237K to $128K due to a significant increase in accounts payable and accrued expenses.
- Debt: Interest expense dropped to zero as all short-term notes payable were repaid in the prior fiscal year.
Outlook, Risks, and Management Commentary
- Going Concern: The independent auditors (Haskell & White LLP) have issued an opinion raising "substantial doubt" about the company's ability to continue as a going concern. The company requires substantial additional financing to fund Phase II trials and operations.
- Financing Needs: Management estimates Phase II trials will cost approximately $2 million and take one year. The company is actively pursuing private financing and strategic alliances.
- Recent Capital Raise: In May 2004 (post-fiscal year), the company closed a $3.03M private placement with foreign investors. As of the filing date, $680K had been received; the remaining $2.35M is pending wire transfer confirmation from a Swiss bank, with no assurance of receipt.
- Risks:
- Failure to obtain FDA approval for Oxycyte.
- Inability to secure necessary funding for Phase II and III trials.
- Competition from other blood substitute technologies (e.g., hemoglobin-based products).
- Lack of commercial manufacturing experience; reliance on third-party contractors.
Investor Verification Checklist
- Capital Confirmation: Verify if the remaining $2.35M from the May 2004 private placement (Remobo AG) has been successfully wired to the company.
- Runway Analysis: Assess if the current cash balance ($302K) plus confirmed new funding is sufficient to complete the estimated $2M Phase II trial budget.
- Regulatory Status: Confirm the submission date and FDA acceptance of the Phase II clinical trial protocol.
- Related Party Transactions: Review the $126K payment to PrimaPharm (contract manufacturer) where an officer of Synthetic Blood is a director and minority shareholder.
- Dilution Risk: Evaluate the impact of outstanding warrants (approx. 6.1M) and options (approx. 5.4M) on existing shareholders, especially given the low share price.